Kybella Double Chin Treatment
Kybella is a new non-surgical treatment, developed by Kythera Biopharmaceuticals, for submental fullness (double chin). The Laser & Skin Surgery Center of New York ® also offers surgical options including liposuction to treat double chins. It is the first and only FDA-approved injectable designed for contouring and reducing fat in the neck. The physicians at the Laser & Skin Surgery Center of New York® participated in the clinical trials of Kybella leading to FDA approval. The Laser & Skin Surgery Center of New York ® is one of the leading centers in the U.S. to offer this revolutionary treatment. Our private patients and patients from our clinical trials have been very satisfied with their results, with improved chin profile and minimal down-time following the procedure. Call to schedule an appointment.
Kybella Patient Brochure
Robert T. Anolik, M.D., of The Laser & Skin Surgery Center of New York, Speaks at a July 2016 Media Event for Kybella
Dr. Geronemus explains how we reduce needle pain during your cosmetic treatment at Laser & Skin Surgery Center of New York
In the News
- The "At-Risk" Chin Get a New Treatment - Yoon-Soo Cindy Bae, M.D. Elle Magazine (2015)
- How a Dermatologist Can Eliminate Your Double Chin With an Injection - Robert T. Anolik, M.D. Cosmopolitan Magazine (2016)
Kybella Related Items
How does it work?
Kybella is a synthetic preparation of deoxycholic acid, a naturally-forming substance in the body that helps break down and absorb dietary fat. When injected into subcutaneous fat under the chin, Kybella promotes the destruction of adipocytes (fat cells). Once destroyed, those cells are unable to store or accumulate fat, leading to a slimmer jawline.
What causes submental fullness (double chin)?
Submental fullness is a common condition that affects adults – both male and female – and is caused by aging, genetics or weight gain. Submental fullness is often resistant to diet and exercise, making it particularly challenging for patients to remedy on their own.
What other treatments are there to reduce submental fullness?
Prior to Kybella's development, more invasive techniques such as liposuction and surgery were the go-to treatment options. Kybella is the only non-invasive treatment available today.
How is Kybella administered?
Kybella is administered by injections into the fat cells under the chin, personalized to the treatment goals of the patient. Each in-office treatment session takes approximately 15-20 minutes.
How many treatments are necessary?
Most patients see a response within two treatments although some patients may require additional treatments depending on the amount of fat that is present.
How quickly do the results appear?
Generally, results appear within weeks to months of treatment.
Are the results permanent?
Kybella is a new product and follow-ups with clinical trials patients need to be conducted. Nevertheless, it is expected that patients would not need retreatment once the aesthetic response is achieved (with diet and lifestyle factors maintained).
What if there is weight gain after treatment with Kybella?
Patients in the clinical trials who gained weight after treatment did not show the return of their submental fullness. However, Kybella is a new product and follow-ups with more patients will provide insight on this topic.
Are there any adverse reactions?
The most common side effects were associated with the injection site and included mild edema (swelling), hematoma (bruising), pain, numbness, and redness following each treatment session.
What are the contraindications?
Kybella is not to be used in patients with a history of dysphagia (difficulty swallowing), bleeding abnormalities, or those currently taking blood thinner medication.
NYU UPN Dermatologists
- Roy G. Geronemus, M.D.
- Robert T. Anolik, M.D.
- Yoon-Soo Cindy Bae, M.D.
- Bradley S. Bloom, M.D.
- Daniel A. Belkin, M.D.
- Roy Seidenberg, M.D.
- Leonard J. Bernstein, M.D.
- Paul M. Friedman, M.D.
- Michelle F. Henry, M.D.
- Jessica J. Krant, M.D.
- Ronald Shelton, M.D.
- Dana Stern, M.D.
- Elliot T. Weiss, M.D.